From Boon to Bubble? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

From Boon to Bubble?
Infrastructure must be in place before jumping into outsourcing.


Pharmaceutical Technology


Michelle Hoffman
I was in business school for the peak of the Internet frenzy, so the effect of the Internet on business practices and the economy was a frequent topic for classroom discussion. At the time, every retailer on earth it seemed was scrambling to develop an online purchasing option. But it didn't take long for many of those early online retailing attempts to fail.


Participate in the annual Pharmaceutical Technology Employment Survey.
One of my professors suggested that retailers who were just slapping up online interface were neglecting to develop the sales and distribution infrastructure to support online retailing. So, while orders might have poured in over the Internet, retailers hadn't put in place the extra personnel required to fill the orders. Missing were the personnel to package and ship merchandise. Retailers had also failed to make the necessary arrangements with their shippers to accommodate all of the extra outgoing mail. The net effect was that orders arrived late (or were inaccurately filled, or both). This was particularly devastating during the Christmas holiday season, when holiday presents ordered over the Internet arrived at their destinations long after the holiday was over. Both consumers and sellers felt burned and retreated for a while from online retailing.

Looking back, the lesson seems so obvious but apparently wasn't at the time, or more retailers would have planned appropriately.

This story may serve as a cautionary tale for the outsourcing industry. This year's survey indicates that drugmakers large and small expect to increase their use of contracted services—a substantial boon for contractors. About a quarter of service providers who responded expect their revenues to grow by 20% or more. But as Jim Miller notes in his cover story, this rapid growth may be straining contractors' resources.

"This is especially true for basic infrastructure capabilities like customer service and project management," writes Miller. Is this starting to sound familiar? Of particular (and particularly ominous) note for service providers, the survey uncovers a gap between customer and service provider definitions of service excellence," Miller notes.




So, sellers beware! All evidence indicates that the outsourcing industry will continue to grow—unless, of course, it gets trapped in a bubble.

Michelle Hoffman is editor-in-chief of Pharmaceutical Technology,
.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here